…We're starting with microdose, not macrodose, which I can explain fully why. And a lot of that's informed by, you know, Matt Johnson, right? So Matt Johnson, our scientific advisory board, Michael Bogenschutz, who's here at NYU, they helped to steer why we…

…not macrodose, which I can explain fully why. And a lot of that's informed by, you know, Matt Johnson, right? So Matt Johnson, our scientific advisory board, Michael Bogenschutz, who's here at NYU, they helped to steer why we would do a microdose and…

…Also, I'm not sure if I'm misrepresenting this, but it was my impression that there was some controversy surrounding Matt Johnson and Fieldtrip's involvement because Fieldtrip is selling a 4-hydroxy-DIPT prodrug as one of their lead compounds. Matt Johnson is…

…surrounding Matt Johnson and Fieldtrip's involvement because Fieldtrip is selling a 4-hydroxy-DIPT prodrug as one of their lead compounds. Matt Johnson is an advisor for Field Trip, and he objected to the scheduling action. So the first wave of controversy,…

…for Field Trip, and he objected to the scheduling action. So the first wave of controversy, which I thought was unfair to Matt Johnson, was that he was only standing up for this because of his financial involvement with Field Trip. How dare he? Well, as…